Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →You can get a GLP-1 online by completing a medical intake with a licensed telehealth provider, having a clinician review your health history and BMI, and, if eligible, receiving a prescription for a branded GLP-1 or a compounded GLP-1 from a licensed 503A pharmacy shipped to your door.
Can you actually get a GLP-1 online?
Yes. GLP-1 online prescribing is possible when a licensed clinician evaluates you through telehealth and decides a prescription is appropriate. The important point is that online care should still be medical care, not a checkout-only process.
GLP-1 receptor agonists act on the glucagon-like peptide-1 pathway, which helps regulate appetite and blood sugar. Tirzepatide is a related GIP/GLP-1 dual agonist. Some medicines in these classes are FDA-approved for chronic weight management in certain adults, but they also carry side effects, contraindications, and monitoring needs [1][2][3].
A safe online program should ask about height, weight, medical history, pregnancy status, medicines, allergies, gallbladder or pancreas history, kidney concerns, stomach conditions, and thyroid cancer history. This matters because semaglutide, tirzepatide, and liraglutide labels include a boxed warning about thyroid C-cell tumors and state that people with a personal or family history of medullary thyroid carcinoma, called MTC, or multiple endocrine neoplasia syndrome type 2, called MEN 2, should not use these products [1][2][3].
Which GLP-1 medications can you get online?
Online clinicians may prescribe different options depending on your indication, health history, insurance, pharmacy access, and state rules. GLP-1 options differ by FDA status, route, dosing schedule, side effects, and cost, so the right choice is a clinician decision, not a simple menu pick.
Branded options: Wegovy, Zepbound, Saxenda, and Foundayo
Wegovy (semaglutide, a GLP-1 receptor agonist; also available as compounded semaglutide through licensed 503A pharmacies when prescribed for an individual patient) is FDA-approved for chronic weight management in certain adults and adolescents and for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. The FDA-approved Wegovy starting dose is 0.25 mg once weekly for 4 weeks, with label titration toward 2.4 mg once weekly when tolerated; common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue, and the label includes the MTC and MEN 2 contraindication [1].
Zepbound (tirzepatide, a GIP/GLP-1 dual agonist; also available as compounded tirzepatide through licensed 503A pharmacies when prescribed for an individual patient) is FDA-approved for chronic weight management in certain adults and for certain adults with obstructive sleep apnea and obesity. The FDA-approved Zepbound starting dose is 2.5 mg once weekly for 4 weeks, with label maintenance doses of 5 mg, 10 mg, or 15 mg once weekly; common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, and the MTC and MEN 2 contraindication [2].
Saxenda (liraglutide, a GLP-1 receptor agonist) is FDA-approved for chronic weight management in certain adults and adolescents. The FDA-approved Saxenda starting dose is 0.6 mg once daily, with label titration toward 3 mg once daily; common side effects include nausea, diarrhea, constipation, vomiting, injection-site reactions, headache, low blood sugar in some patients, and the same boxed warning and contraindications for MTC and MEN 2 [3].
Orforglipron is an oral, non-peptide GLP-1 receptor agonist being studied for weight management and type 2 diabetes. Foundayo is not currently an FDA-approved GLP-1 product for weight loss, so any discussion of Foundayo should be treated as pipeline or brand information unless official FDA labeling changes; in a phase 2 trial, orforglipron was studied at once-daily doses ranging from 12 mg to 45 mg, and nausea, constipation, vomiting, diarrhea, and other gastrointestinal side effects were reported [12].
Compounded semaglutide and compounded tirzepatide via 503A pharmacies
Compounded semaglutide and compounded tirzepatide are not FDA-approved products. Under section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed pharmacies may compound medicines for an identified individual patient when a valid prescription is written, subject to federal and state requirements [4].
Compounded GLP-1s can be part of online care, but they should come from a licensed pharmacy and include clear labeling, storage instructions, side-effect guidance, and follow-up. The FDA has warned that compounded drugs do not go through FDA premarket review for safety, effectiveness, or quality in the same way approved drugs do, and the agency has also warned about dosing errors and salt forms with some compounded semaglutide products [5][6].
What is not typically available online
Ozempic (semaglutide, a GLP-1 receptor agonist) is FDA-approved to improve glycemic control in adults with type 2 diabetes and to reduce certain cardiovascular and kidney risks in labeled groups, but it is not FDA-approved as the weight-loss brand. The FDA-approved Ozempic starting dose is 0.25 mg once weekly for 4 weeks for treatment initiation, with labeled maintenance doses used for diabetes care; common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation, and the MTC and MEN 2 contraindication still applies [7].
Mounjaro (tirzepatide, a GIP/GLP-1 dual agonist) is FDA-approved to improve glycemic control in adults with type 2 diabetes, while Zepbound is the tirzepatide product FDA-approved for chronic weight management in certain adults. The FDA-approved Mounjaro starting dose is 2.5 mg once weekly for 4 weeks, with labeled diabetes maintenance doses after that; common side effects and the boxed warning are similar to Zepbound [2][8].
Who is eligible for a GLP-1 prescription online?
Eligibility depends on the medication label and the clinician’s review. In general, BMI criteria for FDA-approved chronic weight-management medicines include adults with obesity, or adults with overweight plus at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or abnormal cholesterol [1][2][3].
BMI and health-condition criteria
BMI, or body mass index, is a screening tool based on height and weight. It does not tell the whole story, but it helps clinicians decide whether a weight-management medicine fits FDA-labeled criteria and clinical guidelines [9].
A clinician may also review blood pressure, A1C or glucose history, cholesterol, sleep apnea symptoms, pregnancy plans, mental health history, past weight-loss treatments, and current medicines. In clinical trials, semaglutide, tirzepatide, and liraglutide were associated with weight loss for many participants, but individual results vary and side effects were common, especially gastrointestinal symptoms [10][11][13].
Who should not take a GLP-1
People with a personal or family history of MTC or MEN 2 should not use semaglutide, tirzepatide, or liraglutide products with this boxed warning. A clinician may also avoid or delay GLP-1 treatment in people who are pregnant, trying to become pregnant, breastfeeding, or who have certain pancreas, gallbladder, stomach, kidney, or allergy concerns, depending on the medication label and health history [1][2][3].
What are the steps to get a GLP-1 online?
The usual path has 4 main steps: medical intake, clinician review, prescription and pharmacy fulfillment, and follow-up. The safest programs make each step clear before you pay for medication.
- 1Complete a medical intake. You share height, weight, health conditions, medications, allergies, and goals. You may also upload an ID or answer state-specific telehealth questions.
- 2Clinician review and labs if needed. A licensed clinician reviews your intake and may request labs or records, especially if you have diabetes, kidney disease, thyroid history, gallbladder disease, pancreatitis history, or other safety concerns.
- 3Prescription and pharmacy fulfillment. If eligible, the clinician may prescribe an FDA-approved branded product or a compounded GLP-1 from a licensed 503A pharmacy when appropriate for an individual patient [4].
- 4Follow-up and clinician-led dose changes. FDA labels describe stepwise dose escalation for semaglutide, tirzepatide, and liraglutide to help tolerability, but this article does not provide dosing instructions for any reader [1][2][3].
Follow-up is not just a formality. In the STEP 1 trial, participants receiving semaglutide 2.4 mg once weekly had regular lifestyle counseling and safety monitoring; nausea, diarrhea, vomiting, and constipation were more common with semaglutide than placebo [10]. In the SURMOUNT-1 trial, participants receiving tirzepatide 5 mg, 10 mg, or 15 mg once weekly also had structured follow-up, and gastrointestinal side effects were common [11].
How much does a GLP-1 cost online?
GLP-1 cost online can range from low out-of-pocket costs with strong insurance coverage to several hundred dollars or more per month without coverage. Pricing and availability change often and vary by pharmacy, insurance plan, medication, supply, dose form, and program fees.
| Option | FDA status | Common cost factors | Safety notes |
|---|---|---|---|
| FDA-approved branded weight-management medicines such as Wegovy, Zepbound, and Saxenda | FDA-approved for labeled weight-management uses in certain patients [1][2][3] | Insurance coverage, prior authorization, deductible, savings programs, pharmacy stock, visit fees, and follow-up fees | Labels include gastrointestinal side effects, rare serious risks, and contraindications for MTC or MEN 2 [1][2][3] |
| Diabetes-labeled products such as Ozempic or Mounjaro | FDA-approved for type 2 diabetes indications, not as the weight-loss brand names [7][8] | Insurance often depends on diabetes diagnosis and plan rules; off-label weight-loss coverage may be limited | A clinician must review benefits, side effects, contraindications, and appropriate labeled alternatives [7][8] |
| Compounded semaglutide or compounded tirzepatide | Not FDA-approved products; may be compounded by licensed 503A pharmacies for an identified individual patient with a valid prescription [4][5] | Program fee, pharmacy fee, formulation, supplies, shipping, follow-up plan, and state rules | No FDA premarket review for safety, effectiveness, or quality; use requires clinician oversight and a legitimate pharmacy [5][6] |
| Retail pharmacy delivery, including major pharmacy delivery services | Depends on the prescribed product and indication | Insurance network, cash price, stock, delivery availability, cold-chain shipping, and pharmacy rules | A valid prescription is still required; pharmacy delivery is not a substitute for medical evaluation |
How do the main online GLP-1 options compare?
The main choices differ by drug class, FDA indication, and pharmacy path. Semaglutide and tirzepatide have weight-management trial data, but both also have side effects and boxed warnings that require clinician screening [1][2][10][11].
| Medication or category | Drug class | FDA status for weight management | What to know |
|---|---|---|---|
| Wegovy (semaglutide) | GLP-1 receptor agonist | FDA-approved for chronic weight management in labeled groups [1] | FDA label describes 0.25 mg once weekly for 4 weeks as the starting dose and 2.4 mg once weekly as the usual maintenance dose; common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain [1] |
| Zepbound (tirzepatide) | GIP/GLP-1 dual agonist | FDA-approved for chronic weight management in labeled groups [2] | FDA label describes 2.5 mg once weekly for 4 weeks as the starting dose and 5 mg, 10 mg, or 15 mg once weekly as maintenance doses; common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain [2] |
| Saxenda (liraglutide) | GLP-1 receptor agonist | FDA-approved for chronic weight management in labeled groups [3] | FDA label describes 0.6 mg once daily as the starting dose and 3 mg once daily as the recommended maintenance dose; common side effects include nausea, diarrhea, constipation, vomiting, and possible low blood sugar in some patients [3] |
| Ozempic (semaglutide) | GLP-1 receptor agonist | FDA-approved for type 2 diabetes and certain risk reduction uses, not as the weight-loss brand [7] | May come up in online searches, but weight-loss-only use is off-label and requires clinician judgment; label warnings still apply [7] |
| Mounjaro (tirzepatide) | GIP/GLP-1 dual agonist | FDA-approved for type 2 diabetes, not as the weight-loss brand [8] | Zepbound is the tirzepatide brand with the chronic weight-management label; label warnings still apply [2][8] |
| Compounded semaglutide or compounded tirzepatide | Compounded versions of active ingredients used in GLP-1 or GIP/GLP-1 medicines | Not FDA-approved products [4][5] | May be prescribed for an individual patient and prepared by a licensed 503A pharmacy; quality, labeling, storage, and follow-up should be checked carefully [4][5] |
| Orforglipron / Foundayo | Oral GLP-1 receptor agonist under study | Not currently FDA-approved for weight loss | In a phase 2 trial, once-daily orforglipron was studied for weight reduction, with gastrointestinal side effects reported; it is not an approved online prescription option unless FDA labeling changes [12] |
How to get a GLP-1 online through Chia
If you are comparing licensed telehealth options, this kind of program can offer clinician-reviewed access to compounded GLP-1 treatment when appropriate, using prescriptions filled through licensed 503A pharmacy partners. Eligibility depends on medical review, and compounded GLP-1s are not FDA-approved products [4][5].
A responsible online path should explain what is included, what is not included, how follow-up works, which pharmacy fills the prescription, and what to do if side effects occur. It should also make clear that individual results vary and that medication is usually one part of a broader plan that includes nutrition, movement, sleep, and long-term follow-up [9].
3-min quiz
See if you may be eligible
A licensed clinician can review your health history, BMI, goals, and safety risks to decide whether a GLP-1 option is appropriate.
Is it safe to get a GLP-1 online?
It can be safe when care includes a licensed clinician, a valid prescription, a legitimate pharmacy, and follow-up. Safe GLP-1 care should include screening for the boxed warning, pregnancy concerns, pancreas and gallbladder history, kidney issues, stomach conditions, drug interactions, and side effects [1][2][3].
- Avoid websites that sell GLP-1 medicines without a prescription or clinician review.
- Check that the prescriber is licensed in your state.
- Ask which pharmacy fills the prescription and whether it is licensed.
- Confirm whether the product is FDA-approved or compounded.
- Ask how side effects are handled and when to seek urgent care.
- Be cautious with products labeled “research use only,” “not for human use,” or sold without pharmacy labeling.
Common side effects can include nausea, vomiting, diarrhea, constipation, and stomach pain. Serious but less common risks listed in labels include pancreatitis, gallbladder problems, kidney injury related to dehydration, severe gastrointestinal disease concerns, allergic reactions, low blood sugar when used with some diabetes medicines, and worsening diabetic retinopathy in some patients using semaglutide products [1][2][7].
How fast can you get a GLP-1 delivered?
Delivery time depends on clinician review, labs or records, prior authorization, pharmacy stock, shipping rules, and state requirements. GLP-1 delivery may be quick for some eligible patients, but it can take longer when insurance approval or added safety checks are needed.
A faster process is not always a better process. GLP-1 medicines have shown weight-loss benefits in clinical trials, but individual results vary, and the same trials and labels report side effects, contraindications, and monitoring needs [1][2][10][11].
Frequently asked questions
No. You need a licensed clinician review and a valid prescription. Online care can replace an in-person visit for some people, but it should not skip medical screening.
Ozempic is FDA-approved for type 2 diabetes and certain risk reduction uses, not as the weight-loss brand. Weight-loss-only use is off-label and should be discussed with a licensed clinician, including side effects, contraindications, and labeled alternatives [7].
Compounded semaglutide is a non-FDA-approved compounded medication prepared for an individual patient based on a valid prescription. It should come from a licensed pharmacy and be used with clinician oversight [4][5].
Compounded tirzepatide is a non-FDA-approved compounded medication prepared by a licensed pharmacy for an identified patient with a valid prescription. It does not go through FDA premarket review for safety, effectiveness, or quality [4][5].
Not always. Some people use insurance for FDA-approved branded medicines, while others use cash-pay telehealth or pharmacy options. Costs vary by plan, pharmacy, medication, availability, and program fees.
Retail pharmacies may fill eligible GLP-1 prescriptions when they have stock and the prescription is valid. A pharmacy delivery service does not replace the need for clinician evaluation and safety screening.
Some retail or membership programs advertise fixed visit or program fees, but those fees may not include medication, labs, shipping, or insurance costs. Read the program details carefully and confirm who provides clinician care and pharmacy fulfillment.
Timing varies. Some people may complete review and pharmacy fulfillment within days, while others need labs, records, insurance approval, or extra safety review before a prescription can be considered.
AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed clinician still decides whether treatment is appropriate.
3-min quiz
Talk with a licensed clinician
If you are considering an online GLP-1 option, a medical review can help clarify eligibility, safety risks, pharmacy options, and follow-up.
References
- 1.Novo Nordisk. Wegovy (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 2.Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 3.Novo Nordisk. Saxenda (liraglutide) injection prescribing information. U.S. Food and Drug Administration, 2024.
- 4.U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act section 503A: Pharmacy compounding. U.S. Food and Drug Administration, 2024.
- 5.U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2025.
- 6.U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. U.S. Food and Drug Administration, 2024.
- 7.Novo Nordisk. Ozempic (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 8.Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 9.Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation, 2014.
- 10.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 11.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- 12.Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. New England Journal of Medicine, 2023.
- 13.Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 2015.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
